May 29, 2013

Immunovaccine to Present Clinical Data on its DPX-Survivac Cancer Vaccine at the 2013 ASCO Annual Meeting

Study Data Highlights Benefits of Combination Therapy

HALIFAX, NOVA SCOTIA -- (Marketwired) -- 05/29/13 -- Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical stage vaccine company, today announced that data from a clinical study of DPX-Survivac, a therapeutic cancer vaccine, will be presented in the Developmental Therapeutics - Immunotherapy poster session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting. The ASCO Annual Meeting will be held May 31 - June 4, 2013, in Chicago.

The poster presentation will highlight data from Immunovaccine's Phase I clinical trial of DPX-Survivac in patients with ovarian cancer. This trial tested the combination of DPX-Survivac with low dose oral cyclophosphamide. Findings discussed will focus on the safety and immune potential of DPX-Survivac and the effect of cyclophosphamide on vaccine-induced survivin-specific T cell responses.

Details of the poster presentation are as follows:

Abstract #3030:	Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a Phase I study.
	Marc Mansour, Ph.D; Immunovaccine's Chief Science Officer
	Poster Board #22
	Saturday, June 1, 2013, 1:15 - 5:15 p.m.
	Location: S405

Details of the poster discussion session that will follow:

	Saturday, June 1, 2013, 5:30 - 5:45 p.m.
	Location: S406

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting

resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a higher percentage of tumors than other TAA's.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to search actively and specifically for tumor cells and destroy them. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.

About DepoVax

DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the capability for single-dose effectiveness. The DepoVax platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.

About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Immunovaccine Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com
Vida Strategic Partners (media)
Tim Brons
(415) 675-7402

tbrons@vidasp.com

Source: Immunovaccine Inc.